Should we change our clinical practice for Multiple Myeloma based on MRD

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=A3CfMoL0XUs

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: • PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT) • IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM • Bortezomib Dosing - Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM • KarMMA-3 Update - Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis • #ASH #CART #Myeloma #MultipleMyeloma #Cancer #2023 #oncology #oncbrothers • Website: http://www.oncbrothers.com/ • Twitter: / oncbrothers • Contact us at [email protected]

#############################

New on site